Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer

[1]  Y. Hu,et al.  [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[2]  C. A. González-Cruz,et al.  Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases , 2020, The British journal of dermatology.

[3]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[4]  Theodora Psaltopoulou,et al.  Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.

[5]  P. Sidaway.  COVID-19 and cancer: what we know so far , 2020, Nature Reviews Clinical Oncology.

[6]  E. Coomes,et al.  Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.

[7]  S. Recalcati.  Cutaneous manifestations in COVID‐19: a first perspective , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[9]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[10]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[11]  A. Kanani,et al.  Review of cold-induced urticaria characteristics, diagnosis and management in a Western Canadian allergy practice , 2018, Allergy, Asthma & Clinical Immunology.

[12]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Mazières,et al.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies , 2016, Current opinion in oncology.

[14]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.

[15]  G. Piérard,et al.  Revisiting cutaneous adverse reactions to pemetrexed. , 2011, Oncology letters.

[16]  O. Correia,et al.  Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. , 2002, Journal of American Academy of Dermatology.